Published in Ann Neurol on March 01, 2010
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA (2015) 3.48
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement (2014) 2.46
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology (2014) 2.03
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia (2012) 1.90
β-Amyloid affects frontal and posterior brain networks in normal aging. Neuroimage (2010) 1.68
Selective disruption of the cerebral neocortex in Alzheimer's disease. PLoS One (2010) 1.65
Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol (2012) 1.64
The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging (2010) 1.63
Brain network local interconnectivity loss in aging APOE-4 allele carriers. Proc Natl Acad Sci U S A (2011) 1.60
Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain (2010) 1.44
Is AD a homogeneous nosologic entity? Yes. J Neural Transm (Vienna) (2013) 1.39
CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex (2011) 1.38
What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog Neurobiol (2014) 1.29
Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol (2013) 1.28
Aβ Deposition in aging is associated with increases in brain activation during successful memory encoding. Cereb Cortex (2011) 1.26
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.25
Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain (2011) 1.23
Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology (2011) 1.23
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin (2013) 1.21
Accelerating cortical thinning: unique to dementia or universal in aging? Cereb Cortex (2012) 1.20
Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther (2011) 1.07
The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognition. Neuroimage (2013) 1.05
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. Neuroimage Clin (2013) 1.02
Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain (2015) 1.01
Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiol Aging (2012) 0.99
Brain imaging in the study of Alzheimer's disease. Neuroimage (2011) 0.97
Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications. Clinics (Sao Paulo) (2011) 0.96
Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. JAMA Neurol (2015) 0.94
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol (2014) 0.93
Staging Alzheimer's disease progression with multimodality neuroimaging. Prog Neurobiol (2011) 0.92
Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol (2013) 0.92
Event-related potential markers of brain changes in preclinical familial Alzheimer disease. Neurology (2011) 0.91
Association of gray matter atrophy with age, β-amyloid, and cognition in aging. Cereb Cortex (2013) 0.91
Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain (2014) 0.91
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging (2013) 0.90
Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One (2012) 0.90
The role of hippocampal iron concentration and hippocampal volume in age-related differences in memory. Cereb Cortex (2012) 0.90
CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. Brain Imaging Behav (2012) 0.90
Scoring by nonlocal image patch estimator for early detection of Alzheimer's disease. Neuroimage Clin (2012) 0.90
In vivo human amyloid imaging. Curr Alzheimer Res (2011) 0.90
Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. Neurobiol Aging (2011) 0.90
Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. Alzheimers Dement (2012) 0.90
Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? Neuroimage Clin (2013) 0.89
Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. PLoS One (2013) 0.89
Role of structural MRI in Alzheimer's disease. Alzheimers Res Ther (2010) 0.88
GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain (2015) 0.88
Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. Am J Geriatr Psychiatry (2013) 0.87
Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: the AIBL Active trial. BMC Psychiatry (2012) 0.87
The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimers Dement (2014) 0.87
Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. Neurobiol Aging (2013) 0.86
Minimal atrophy of the entorhinal cortex and hippocampus: progression of cognitive impairment. Dement Geriatr Cogn Disord (2011) 0.86
Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. Front Aging Neurosci (2014) 0.86
Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. Eur J Nucl Med Mol Imaging (2014) 0.86
Amyloid burden in the hippocampus and default mode network: relationships with gray matter volume and cognitive performance in mild stage Alzheimer disease. Medicine (Baltimore) (2015) 0.85
A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int (2014) 0.85
Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly. Neurology (2015) 0.85
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurol (2016) 0.84
Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement (2014) 0.84
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 0.83
The adverse impact of type 2 diabetes on brain volume in heart failure. J Clin Exp Neuropsychol (2013) 0.83
Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. EJNMMI Res (2013) 0.83
Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurol (2015) 0.82
Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function? Cereb Cortex (2013) 0.81
Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Ann Neurol (2013) 0.81
Multimodal MRI-based Imputation of the Aβ+ in Early Mild Cognitive Impairment. Ann Clin Transl Neurol (2014) 0.81
Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ε4 carriers. Neuroimage Clin (2013) 0.81
Aβ-related hyperactivation in frontoparietal control regions in cognitively normal elderly. Neurobiol Aging (2015) 0.80
Apathy is associated with lower inferior temporal cortical thickness in mild cognitive impairment and normal elderly individuals. J Neuropsychiatry Clin Neurosci (2014) 0.80
Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease. Neuroimage Clin (2014) 0.80
Differences in learning rates for item and associative memories between amnestic mild cognitive impairment and healthy controls. Behav Brain Funct (2013) 0.80
Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease. Front Aging Neurosci (2017) 0.79
Memory concerns, memory performance and risk of dementia in patients with mild cognitive impairment. PLoS One (2014) 0.79
Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment. J Geriatr Psychiatry Neurol (2015) 0.79
Biomarkers in Alzheimer's disease. Front Neurol (2011) 0.79
Impact of SORL1 genetic variations on MRI markers in non-demented elders. Oncotarget (2016) 0.78
Atrophic Patterns of the Frontal-Subcortical Circuits in Patients with Mild Cognitive Impairment and Alzheimer's Disease. PLoS One (2015) 0.78
Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics (2016) 0.78
Are AD-Typical Regions the Convergence Point of Multiple Pathologies? Front Aging Neurosci (2015) 0.78
Effect of Alzheimer's Disease Risk Variant rs3824968 at SORL1 on Regional Gray Matter Volume and Age-Related Interaction in Adult Lifespan. Sci Rep (2016) 0.78
MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Front Aging Neurosci (2017) 0.78
Kinetics of neurodegeneration based on a risk-related biomarker in animal model of glaucoma. Mol Neurodegener (2013) 0.77
Altered whole-brain white matter networks in preclinical Alzheimer's disease. Neuroimage Clin (2015) 0.77
Associations of cerebrovascular and Alzheimer's disease pathology with brain atrophy. Curr Alzheimer Res (2014) 0.77
Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease. Hum Brain Mapp (2012) 0.77
Beyond diagnosis: what biomarkers are teaching us about the "bio"logy of Alzheimer disease. Ann Neurol (2010) 0.77
Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months. PLoS One (2015) 0.77
Alzheimer's disease: Unique markers for diagnosis & new treatment modalities. Indian J Med Res (2015) 0.77
A Novel Cognitive Stress Test for the Detection of Preclinical Alzheimer Disease: Discriminative Properties and Relation to Amyloid Load. Am J Geriatr Psychiatry (2016) 0.77
Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain (2016) 0.77
Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. Front Neurosci (2017) 0.76
Alpha band disruption in the AD-continuum starts in the Subjective Cognitive Decline stage: a MEG study. Sci Rep (2016) 0.75
Metabolic Alterations Associated to Brain Dysfunction in Diabetes. Aging Dis (2015) 0.75
Advances in development of fluorescent probes for detecting amyloid-β aggregates. Acta Pharmacol Sin (2016) 0.75
Hippocampal Amyloid Burden with Downstream Fusiform Gyrus Atrophy Correlate with Face Matching Task Scores in Early Stage Alzheimer's Disease. Front Aging Neurosci (2016) 0.75
Imago Mundi, Imago AD, Imago ADNI. Alzheimers Res Ther (2014) 0.75
Palmomental Reflex a Relevant Sign in Early Alzheimer's Disease Diagnosis? J Alzheimers Dis (2015) 0.75
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
The Accelerated Child Survival and Development programme in west Africa: a retrospective evaluation. Lancet (2010) 6.56
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov (2004) 5.82
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol (2002) 3.30
PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol (2006) 3.12
WHO and UNICEF estimates of national infant immunization coverage: methods and processes. Bull World Health Organ (2009) 3.10
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Street lighting disturbs commuting bats. Curr Biol (2009) 2.95
Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurol (2007) 2.88
Levels and trends in under-5 mortality, 1990-2008. Lancet (2009) 2.86
A primer of amyloid nomenclature. Amyloid (2007) 2.70
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr (2009) 2.54
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet (2011) 2.50
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry (2003) 2.50
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target? Acta Neuropathol (2014) 2.25
Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2005) 2.14
Sexual function in the late postmenopause: a decade of follow-up in a population-based cohort of Australian women. J Sex Med (2014) 2.12
MRI-guided prostate radiation therapy planning: Investigation of dosimetric accuracy of MRI-based dose planning. Radiother Oncol (2011) 2.09
Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry (2004) 2.05
Fibre diffraction of hair can provide a screening test for Alzheimer's disease: a human and animal model study. Med Sci Monit (2005) 2.01
Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care (2013) 1.99
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J (2005) 1.98
C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet (2006) 1.97
Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev (2003) 1.97
A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry (2002) 1.93
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med (2013) 1.93
Levels and trends in child mortality, 1990-2009. Lancet (2010) 1.92
Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging. Brain (2011) 1.92
Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet (2003) 1.91
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement (2013) 1.87
IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol (2003) 1.86
Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci (2008) 1.86
Taxon-specific PCR for DNA barcoding arthropod prey in bat faeces. Mol Ecol Resour (2010) 1.84
Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci (2005) 1.83
In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging (2014) 1.80
Cognitive impairment and vitamin B12: a review. Int Psychogeriatr (2012) 1.78
Fellatio by fruit bats prolongs copulation time. PLoS One (2009) 1.77
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem (2002) 1.74
Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr (2002) 1.73
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain (2011) 1.67
PrPC-related signal transduction is influenced by copper, membrane integrity and the alpha cleavage site. Cell Res (2009) 1.64
The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem (2004) 1.63